Huntington’s disease has been extensively studied in symptomatic stages at genomic, epigenomic, and proteomic levels, finding that the lengths of the CAG segment of the Huntingtin gene influence alterations in acetylation levels, which translates into changes in regulatory events and ultimately guides neurodegenerative processes and cellular and glial identity [36,37,38]. This evidence concerns the gene HTT and Huntington disease.